98 related articles for article (PubMed ID: 11519066)
1. Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients.
Cerea K; Romano F; Bravo AF; Motta V; Uggeri F; Brivio F; Fumagalli LA; Uggeri F
J Surg Oncol; 2001 Sep; 78(1):32-7. PubMed ID: 11519066
[TBL] [Abstract][Full Text] [Related]
2. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
3. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
4. Radical surgery does not recover immunodeficiency associated with gastric cancer.
Romano F; Caprotti R; Bravo AF; Conti M; Colombo G; Piacentini G; Uggeri F; Uggeri F
J Exp Clin Cancer Res; 2003 Jun; 22(2):179-83. PubMed ID: 12866567
[TBL] [Abstract][Full Text] [Related]
5. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.
Masotti A; Morandini G; Ortolani R; Fumagalli L
Lung Cancer; 1998 Jun; 20(3):191-202. PubMed ID: 9733054
[TBL] [Abstract][Full Text] [Related]
6. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
[TBL] [Abstract][Full Text] [Related]
7. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
[TBL] [Abstract][Full Text] [Related]
8. Short-term preoperative IL-2 immunotherapy in operable pancreatic cancer: a randomized study.
Uggeri F; Caprotti R; De Grate L; Crippa S; Nobili C; Penati C; Romano F
Hepatogastroenterology; 2009; 56(91-92):861-5. PubMed ID: 19621718
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
10. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
11. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
13. [Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
Scardino E; Lissoni P; Andres M; Frea B; Favini P; Kocjancic E; Verweij F; Barani S; Tancini G; Rocco F
Arch Ital Urol Androl; 1997 Feb; 69(1):49-54. PubMed ID: 9181906
[TBL] [Abstract][Full Text] [Related]
14. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
16. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
17. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study.
Franciosi CM; Piacentini MG; Conti M; Romano F; Musco F; Caprotti R; Rovelli F; Uggeri F
Hepatogastroenterology; 2003; 50(49):297-300. PubMed ID: 12630045
[TBL] [Abstract][Full Text] [Related]
18. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
Brivio F; Lissoni P; Barni S; Tancini G; Ardizzoia A; Erba L; Alderi G; Nociti V
Eur J Surg; 1993 Jan; 159(1):43-7. PubMed ID: 8095806
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.
Davey RT; Chaitt DG; Piscitelli SC; Wells M; Kovacs JA; Walker RE; Falloon J; Polis MA; Metcalf JA; Masur H; Fyfe G; Lane HC
J Infect Dis; 1997 Apr; 175(4):781-9. PubMed ID: 9086130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
